1 min read
Add as a preferred source on GooglePROCEPT BioRobotics Targets Positive Adjusted EBITDA in Q4 2026
The company projects 2026 revenue of $390 million to $410 million and a full-year adjusted EBITDA loss of $30 million to $35 million.
PROCEPT BioRobotics is targeting positive adjusted EBITDA in Q4 2026, alongside a 2026 revenue outlook of $390 million to $410 million.
The company’s full-year adjusted EBITDA outlook is a loss of $30 million to $35 million. The positive target applies to the fourth quarter, while the loss range covers the year.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.